Bruce A. Cohen

VitaPath Genetics is developing a family of DNA tests to help individuals reduce the risk of serious and life-threatening disease. The company's first product is a genetic test to identify risk factors that are associated with a common birth defect called Spina Bifida and which can be safely corrected with low-risk vitamin supplementation under the care of a physician. At VitaPath, it mission is to focus only on genetic mutations that are shown to be biologically functional and that can be remediated with minimal risk. In doing so, it can improve the quality of life for customers and reduce the overall cost of healthcare.

SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million.

Cerca Insights Sdn. Bhd. provides behavioral pharmacology paradigms to research institutes. It services include phenotyping new rodent models, sar support, identifying and optimising leads, behavioural assay development, PK screens and PD analysis, early safety assessment, ageing studies and chronic dosing. The company was founded by Anil K. Ratty in 2008 and is headquartered in Bayan Lepas, Malaysia.

Baysient LLC is a private company that creates cloud-based software to facilitate individualized dosing of anti-inflammatory mabs to improve outcomes in patients. The company is based in Fort Myers, FL. The software uses Bayesian models, routine lab results, and demographics to individualize dosing to a specified target trough-level output to a PK dashboard. Steven A. Molnar has been the CEO of the company since 2019.

Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA.

PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore.

Chrono Therapeutics, Inc. produces transdermal drug products. It is a pharmaceutical company with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery that offers real-time behavioral support. The company was founded by Guy DiPierro in 2004 and is headquartered in Hayward, CA.